However, activated lipid metabolism in tumor potentiates melanoma immunogenicity and thereby increases its sensitivity to T cell-mediated killing, rendering a higher response rate to anti-PD-1 immunotherapy (21). This evidence concerns the gene PDCD1 and neoplasm.